These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27216304)

  • 21. Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
    Elgersma RC; Coumans RG; Huijbregts T; Menge WM; Joosten JA; Spijker HJ; de Groot FM; van der Lee MM; Ubink R; van den Dobbelsteen DJ; Egging DF; Dokter WH; Verheijden GF; Lemmens JM; Timmers CM; Beusker PH
    Mol Pharm; 2015 Jun; 12(6):1813-35. PubMed ID: 25635711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.
    Loganzo F; Tan X; Sung M; Jin G; Myers JS; Melamud E; Wang F; Diesl V; Follettie MT; Musto S; Lam MH; Hu W; Charati MB; Khandke K; Kim KS; Cinque M; Lucas J; Graziani E; Maderna A; O'Donnell CJ; Arndt KT; Gerber HP
    Mol Cancer Ther; 2015 Apr; 14(4):952-63. PubMed ID: 25646013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.
    Pillow TH; Schutten M; Yu SF; Ohri R; Sadowsky J; Poon KA; Solis W; Zhong F; Del Rosario G; Go MAT; Lau J; Yee S; He J; Liu L; Ng C; Xu K; Leipold DD; Kamath AV; Zhang D; Masterson L; Gregson SJ; Howard PW; Fang F; Chen J; Gunzner-Toste J; Kozak KK; Spencer S; Polakis P; Polson AG; Flygare JA; Junutula JR
    Mol Cancer Ther; 2017 May; 16(5):871-878. PubMed ID: 28223423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
    Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
    Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping.
    Khera E; Cilliers C; Smith MD; Ganno ML; Lai KC; Keating TA; Kopp A; Nessler I; Abu-Yousif AO; Thurber GM
    Neoplasia; 2021 Feb; 23(2):210-221. PubMed ID: 33385970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
    Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
    Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody-Drug Conjugates.
    Neumann CS; Olivas KC; Anderson ME; Cochran JH; Jin S; Li F; Loftus LV; Meyer DW; Neale J; Nix JC; Pittman PG; Simmons JK; Ulrich ML; Waight AB; Wong A; Zaval MC; Zeng W; Lyon RP; Senter PD
    Mol Cancer Ther; 2018 Dec; 17(12):2633-2642. PubMed ID: 30242091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer.
    Bhakta S; Crocker LM; Chen Y; Hazen M; Schutten MM; Li D; Kuijl C; Ohri R; Zhong F; Poon KA; Go MAT; Cheng E; Piskol R; Firestein R; Fourie-O'Donohue A; Kozak KR; Raab H; Hongo JA; Sampath D; Dennis MS; Scheller RH; Polakis P; Junutula JR
    Mol Cancer Ther; 2018 Mar; 17(3):638-649. PubMed ID: 29282299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry.
    Ekholm FS; Pynnönen H; Vilkman A; Pitkänen V; Helin J; Saarinen J; Satomaa T
    ChemMedChem; 2016 Nov; 11(22):2501-2505. PubMed ID: 27786414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
    Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP
    J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation.
    Bai C; Reid EE; Wilhelm A; Shizuka M; Maloney EK; Laleau R; Harvey L; Archer KE; Vitharana D; Adams S; Kovtun Y; Miller ML; Chari R; Keating TA; Yoder NC
    Bioconjug Chem; 2020 Jan; 31(1):93-103. PubMed ID: 31747250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates.
    Hinrichs MJM; Ryan PM; Zheng B; Afif-Rider S; Yu XQ; Gunsior M; Zhong H; Harper J; Bezabeh B; Vashisht K; Rebelatto M; Reed M; Ryan PC; Breen S; Patel N; Chen C; Masterson L; Tiberghien A; Howard PW; Dimasi N; Dixit R
    Clin Cancer Res; 2017 Oct; 23(19):5858-5868. PubMed ID: 28630216
    [No Abstract]   [Full Text] [Related]  

  • 34. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads.
    Puthenveetil S; Loganzo F; He H; Dirico K; Green M; Teske J; Musto S; Clark T; Rago B; Koehn F; Veneziale R; Falahaptisheh H; Han X; Barletta F; Lucas J; Subramanyam C; O'Donnell CJ; Tumey LN; Sapra P; Gerber HP; Ma D; Graziani EI
    Bioconjug Chem; 2016 Aug; 27(8):1880-8. PubMed ID: 27412791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
    Staudacher AH; Brown MP
    Br J Cancer; 2017 Dec; 117(12):1736-1742. PubMed ID: 29065110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET.
    Terwisscha van Scheltinga AG; Ogasawara A; Pacheco G; Vanderbilt AN; Tinianow JN; Gupta N; Li D; Firestein R; Marik J; Scales SJ; Williams SP
    Mol Cancer Ther; 2017 Jan; 16(1):134-142. PubMed ID: 27760836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy.
    Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC
    Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation.
    Stefan N; Gébleux R; Waldmeier L; Hell T; Escher M; Wolter FI; Grawunder U; Beerli RR
    Mol Cancer Ther; 2017 May; 16(5):879-892. PubMed ID: 28258164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.